Avacta Group plc (AVCT) Ordinary Shares 10p
![](https://online.hl.co.uk/img/hl/layout/security-up-arrow.gif)
- Add to watchlist
- Create an alert
- This stock can be held in a
![](https://online.hl.co.uk/img/hl/layout/security-up-arrow.gif)
![Deal now](https://online.hl.co.uk/img/form-buttons/deal-now-button.jpg)
![](https://online.hl.co.uk/img/hl/layout/security-up-arrow.gif)
![Deal now](https://online.hl.co.uk/img/form-buttons/deal-now-button.jpg)
Business summary
Avacta Group plc is a United Kingdom-based life sciences company focused on improving healthcare outcomes through targeted cancer treatments and diagnostics. The Company has two segments: Therapeutics and Diagnostics. The Therapeutics segment is a clinical stage oncology biotech division harnessing therapeutic platforms to develop novel, highly targeted cancer drugs. The Diagnostics segment is focused on supporting healthcare professionals and broadening access to diagnostics. It has two platforms: preICISION and Affimer. The Company's preICISION platform is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The preICISION platform harnesses this tumor specific protease to activate preICISION peptide drug conjugates and preICISION antibody/Affimer drug conjugates in the tumor microenvironment. Its lead preICISION program AVA6000, a peptide drug conjugate form of doxorubicin, is in Phase 1 studies.
Contact details
Important dates
General stock information
- EPIC:
- AVCT
- ISIN:
- GB00BYYW9G87
- Market cap:
- £251.16 million
- Shares in issue:
- 356.26 million
- Sector:
- Pharmaceuticals & Biotechnology
- Exchange:
- London Stock Exchange
- Currency:
- Sterling pence
- Indices:
- n/a
Key personnel
![Deal now](https://online.hl.co.uk/img/form-buttons/deal-now-button.jpg)
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.